Shopping Cart
- Remove All
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
100 mg | Inquiry | Backorder | |
500 mg | Inquiry | Backorder |
Description | AlbA-DCA is a conjugate formed by the attachment of Albiziabioside A to a dichloroacetate acid subunit. It can induce a marked increase in intracellular ROS and alleviate the accumulation of lactic acid in the tumor microenvironment, and also selectively |
In vitro | AlbA-DCA exhibits the cytotoxicity against the MCF-7 cells, HCT116 cells, A375 cells, 4T1 cells, HBMEC cells and LO2 cells (IC50s: 0.43 μM, 3.87 μM, 3.78 μM, 1.31 μM, 38.20 μM and 53.14 μM). AlbA-DCA (2 μM; 24 hours) treatment induces apoptotic cell death in MCF-7 cells. AlbA-DCA (2 μM; MCF-7 cells) treatment could significantly up-regulate the expression of cytochrome c and down-regulate the expression of anti-apoptotic protein Bcl-2. AlbA-DCA significantly enhances the expression of caspase-9. |
In vivo | AlbA-DCA (2 mg/kg; subcutaneous injection; every 2 days; for 2 weeks; nude mice) treatment displays antitumor efficacy and almost completely suppresses tumor progression, and no mouse deaths and no significant changes in body weight are observed. AlbA-DCA has no obvious toxicity of liver and kidney and no major abnormality is observed in the heart, liver, spleen, lung, and kidney. |
Molecular Weight | 860.9 |
Formula | C43H67Cl2NO12 |
Cas No. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.